...
首页> 外文期刊>癌と化学療法 >A case of long surviving advanced recurrent breast cancer with multiple bone metastases responding to treatment with 5'-DFUR combined with MPA
【24h】

A case of long surviving advanced recurrent breast cancer with multiple bone metastases responding to treatment with 5'-DFUR combined with MPA

机译:具有多种骨转移的患者长期存活的乳腺癌的案例,响应5'-DFUR与MPa合并治疗

获取原文
获取原文并翻译 | 示例

摘要

The patient was a 69-year-old woman who had undergone right standard radical mastectomy on August 8, 1991, and was treated with chemo- and hormonal therapy of ADM, UFT and TMA. Three years later she showed multiple bone metastases with elevation of CEA, and 5'-DFUR 1,200 mg/day and MPA 800 mg/day were administered. Two years later her CEA levels were decreased, 5'-DFUR was discontinued and MPA 1,200 mg/day only was continued. Two months later a side effect of MPA, her body weight gain, was observed, and the dosage of MPA was reduced from 1,200 mg/day to 800 mg/day. Then the side effect was resolved. Bone scintigraphy and MRI showed that bone metastatic lesions were reduced 6 years after 5'-DFUR and MPA therapy. It is suggested that this combination therapy may be useful for advanced recurrent breast cancer patients with multiple bone metastases.
机译:患者是一名69岁的女性,1991年8月8日,经过了右标准的自由基乳房切除术,并用ADM,UFT和TMA的化学和激素治疗治疗。 三年后,她展示了CEA升高的多种骨转移,并施用5'-DFUR 1,200毫克/天和MPA 800mg /天。 两年后,她的CEA水平降低,停止5'-DFUR,仅继续MPA 1,200毫克/天。 两个月后,观察到MPa,身体体重增加的副作用,MPa的用量从1,200mg /天降至800mg /天。 然后解决了副作用。 骨闪烁和MRI表明,5'-DFUR和MPA治疗后6年减少了骨转移性病变。 建议这种联合治疗对于具有多种骨转移率的晚期复发性乳腺癌患者可能是有用的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号